Arvinas, Inc. announced promising preclinical results for ARV-393, a targeted protein degrader aimed at treating non-Hodgkin lymphoma, particularly high grade B-cell lymphomas. Data showed that ...

Arvinas will present preclinical data on ARV-393's potential in lymphoma treatment at the AACR Annual Meeting. Quiver AI Summary. Arvinas, Inc., a biotechnology company focused on targeted protein ...

Arvinas Inc. – Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 ...